Literature DB >> 23589196

Parkinson's disease: an update on pathogenesis and treatment.

Tom Foltynie1, Joshua Kahan.   

Abstract

The Parkinson's disease research field is a rapidly moving one, as many of the relevant processes underlying PD neurodegeneration are being deciphered, enabling novel approaches to treatment to be assessed both in the laboratory and in the clinic. This review aims to highlight the most relevant updates in the PD field, with emphasis on research that may help lead towards an improvement in the treatment of this condition.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23589196     DOI： 10.1007/s00415-013-6915-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  75 in total

1.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

2.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

3.  A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Authors:  C Warren Olanow; Robert A Hauser; Joseph Jankovic; William Langston; Anthony Lang; Werner Poewe; Eduardo Tolosa; Fabrizio Stocchi; Eldad Melamed; Eli Eyal; Olivier Rascol
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

4.  PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.

Authors:  Joo-Ho Shin; Han Seok Ko; Hochul Kang; Yunjong Lee; Yun-Il Lee; Olga Pletinkova; Juan C Troconso; Valina L Dawson; Ted M Dawson
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

5.  AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Authors:  Daniela Berg; Jana Godau; Claudia Trenkwalder; Karla Eggert; Iiona Csoti; Alexander Storch; Heiko Huber; Monica Morelli-Canelo; Maria Stamelou; Vincent Ries; Martin Wolz; Christine Schneider; Thérèse Di Paolo; Fabrizio Gasparini; Sam Hariry; Marc Vandemeulebroecke; Walid Abi-Saab; Katy Cooke; Donald Johns; Baltazar Gomez-Mancilla
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

6.  Serum urate and the risk of Parkinson's disease: results from a meta-analysis.

Authors:  Chunhong Shen; Yi Guo; Wei Luo; Chen Lin; Meiping Ding
Journal:  Can J Neurol Sci       Date:  2013-01       Impact factor: 2.104

7.  A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

8.  Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms.

Authors:  Maria G Cersosimo; Gabriela B Raina; Cristina Pecci; Alejandro Pellene; Cristian R Calandra; Cristiam Gutiérrez; Federico E Micheli; Eduardo E Benarroch
Journal:  J Neurol       Date:  2012-12-21       Impact factor: 4.849

9.  The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.

Authors:  Raquel Duran; Niccolo E Mencacci; Aikaterini V Angeli; Maryam Shoai; Emma Deas; Henry Houlden; Atul Mehta; Derralynn Hughes; Timothy M Cox; Patrick Deegan; Anthony H Schapira; Andrew J Lees; Patricia Limousin; Paul R Jarman; Kailash P Bhatia; Nicholas W Wood; John Hardy; Tom Foltynie
Journal:  Mov Disord       Date:  2012-12-05       Impact factor: 10.338

10.  Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease.

Authors:  Joshua A Goldberg; Jaime N Guzman; Chad M Estep; Ema Ilijic; Jyothisri Kondapalli; Javier Sanchez-Padilla; D James Surmeier
Journal:  Nat Neurosci       Date:  2012-09-02       Impact factor: 24.884
View more
  11 in total

Review 1.  Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia.

Authors:  Ed Needham; Michael S Zandi
Journal:  J Neurol       Date:  2014-09-03       Impact factor: 4.849

Review 2.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

3.  Zirconium oxide ceramic foam: a promising supporting biomaterial for massive production of glial cell line-derived neurotrophic factor.

Authors:  Zhong-wei Liu; Wen-qiang Li; Jun-kui Wang; Xian-cang Ma; Chen Liang; Peng Liu; Zheng Chu; Yong-hui Dang
Journal:  J Zhejiang Univ Sci B       Date:  2014-12       Impact factor: 3.066

Review 4.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

5.  Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat.

Authors:  Siamak Afshin-Majd; Mohsen Khalili; Mehrdad Roghani; Narges Mehranmehr; Tourandokht Baluchnejadmojarad
Journal:  Mol Neurobiol       Date:  2014-06-18       Impact factor: 5.590

6.  Protective effects of salidroside in the MPTP/MPP(+)-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway.

Authors:  Songhai Wang; Hong He; Lei Chen; Wei Zhang; Xiaojun Zhang; Jianzong Chen
Journal:  Mol Neurobiol       Date:  2014-06-07       Impact factor: 5.590

7.  Association analysis of HLA-DRA in Chinese patients with sporadic Parkinson's disease.

Authors:  Ming-Shu Mo; You-Sheng Xiao; Zhuo-Hua Wu; Cong-Cong Sun; Li-Min Zhang; Luan Cen; Xiang Chen; Shao-Gang Qu; Xin-Ling Yang; Ping-Yi Xu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-12-25

8.  Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease.

Authors:  Anna L Stern; Nirinjini Naidoo
Journal:  Springerplus       Date:  2015-01-17

9.  Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway.

Authors:  Leitao Wu; Hang Xu; Liang Cao; Tao Li; Ruru Li; Yang Feng; Jianzong Chen; Jing Ma
Journal:  Evid Based Complement Alternat Med       Date:  2017-09-28       Impact factor: 2.629

10.  Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.

Authors:  Ming-Shu Mo; Wei Huang; Cong-Cong Sun; Li-Min Zhang; Luan Cen; You-Sheng Xiao; Guo-Fei Li; Xin-Ling Yang; Shao-Gang Qu; Ping-Yi Xu
Journal:  Chin Med J (Engl)       Date:  2016-05-05       Impact factor: 2.628
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.